Benzy Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 08-07-2024
- Paid Up Capital ₹ 0.10 M
as on 08-07-2024
- Company Age 13 Year, 2 Months
- Last Filing with ROC 31 Mar 2022
- Revenue %
(FY 2021)
- Profit -1286.21%
(FY 2021)
- Ebitda -649.37%
(FY 2021)
- Net Worth -171.64%
(FY 2021)
- Total Assets 14.33%
(FY 2021)
About Benzy Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Abdul Veetil, Noorjhan Nazar, and Benazir Nazar serve as directors at the Company.
- CIN/LLPIN
U24233KL2011PTC029529
- Company No.
029529
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Oct 2011
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Malappuram, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Benzy Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abdul Veetil  | Director | 07-Oct-2011 | Current |
| Noorjhan Nazar | Director | 07-Oct-2011 | Current |
| Benazir Nazar | Director | 16-Dec-2020 | Current |
Financial Performance of Benzy Pharma.
Benzy Pharma Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 1286.21% decrease in profit. The company's net worth observed a substantial decline by a decrease of 171.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Benzy Pharma?
In 2021, Benzy Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Federation Of Indian Emigrants Management Councils & AssociationsActive 27 years 3 monthsAbdul Veetil is a mutual person
Akbar Travels Of India Private LimitedActive 23 years 2 monthsAbdul Veetil and Noorjhan Nazar are mutual person
Benzy Food And Beverages Private LimitedActive 28 years 10 monthsAbdul Veetil, Noorjhan Nazar and 1 more are mutual person
Akbar Online Booking Company Private LimitedActive 17 years 7 monthsAbdul Veetil, Noorjhan Nazar and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Benzy Pharma?
Unlock and access historical data on people associated with Benzy Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Benzy Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Benzy Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
